Erin Michos, MD
LightNews LightNews
banner
erinmichos.bsky.social
Erin Michos, MD
@erinmichos.bsky.social
5.1K followers 1.5K following 95 posts
Cardiologist 🫀 & Researcher (women's health & CVD prevention). Professor at Johns Hopkins School of Medicine. Mother of a teenager. Loves travel ✈️, Barre classes, running 🏃‍♀️, & coffee ☕️ . She/hers
Posts Replies Media Videos
Reposted by Erin Michos, MD
rblument1.bsky.social
Excellent presentation by Professor Erin Michos @erinmichos.bsky.social at #AHA25
November 8, 2025 at 4:40 PM
erinmichos.bsky.social
Congratulations to our @hopkinsheart.bsky.social research fellow Dr @zaibhussain10.bsky.social on being a #QCOR Early Career Finalist at #AHA2025 ! 👏👏Check out her presentation Friday with simultaneous publication in Circ Outcomes on motivational themes for CV trial enrollment.
November 6, 2025 at 6:01 PM
Reposted by Erin Michos, MD
allisonghaysmd.bsky.social
🚨 Don’t miss the Early Career Investigators Session #AHA2025! Groundbreaking @hopkinsheart.bsky.social research on maternal mortality and CVD risk to be featured w/ simultaneous pub in Circulation. Congrats to coauthors and Hopkins team lead by Anum Minhas and Theresa Boyer @erinmichos.bsky.social
November 6, 2025 at 5:35 PM
erinmichos.bsky.social
FINE-ONE was just presented at @asnkidney.bsky.social at #KidneyWk. #Finerenone significantly reduced #UACR by 25% at 6 months in patients with #T1D & #CKD - an understudied population with high unmet need.
November 6, 2025 at 3:08 PM
erinmichos.bsky.social
Pleased to take part in this podcast about "Diagnostic Strategies for the Timely Detection of Familial Chylomicronemia Syndrome" with Dr Archna Bajaj. #FCS #lipids
Sponsored by @vindicomeded.bsky.social & @gohealio.bsky.social

www.healio.com/cme/mededtal...
Diagnostic Strategies for the Timely Detection of FCS With Drs. Archna Bajaj and Erin Michos
www.healio.com
November 2, 2025 at 5:45 PM
Reposted by Erin Michos, MD
allisonghaysmd.bsky.social
Great @hopkinsheart.bsky.social representation @ase360.bsky.social @mmukherjeemd.bsky.social @erinmichos.bsky.social
September 7, 2025 at 9:50 PM
Reposted by Erin Michos, MD
allisonghaysmd.bsky.social
Excellent session on women’s heart health across the lifespan and role of Echo at #ASE2025
Featuring @erinmichos.bsky.social (women’s health leader @HopkinsHeart) @anabarac (pioneer in cardio-oncology), masterfully chaired by @sharonmulvagh expert in Echo and women’s CV health
September 7, 2025 at 9:29 PM
Reposted by Erin Michos, MD
ajpcardio.bsky.social
New study alert: Women with established coronary artery disease are less likely than men to receive guideline-based statin therapy—and face higher rates of recurrent cardiovascular events. Ensuring equal treatment equity could save more lives. Read more: www.sciencedirect.com/science/arti...
August 11, 2025 at 5:25 PM
Reposted by Erin Michos, MD
endocrinologyadv.bsky.social
Changes in #BoneMineralDensity were mediated by changes in E2 and testosterone among women and men, respectively, with #T2D undergoing weight loss.

@erinmichos.bsky.social @johnshopkinssph.bsky.social @jhu.edu @imperialcollegeldn.bsky.social @uthsc.bsky.social
Weight Loss-Induced Sex Hormone Changes May Affect BMD Loss in T2D
Weight loss-induced sex hormone changes had a mediating effect on bone mineral density loss among patients with type 2 diabetes.
www.endocrinologyadvisor.com
July 23, 2025 at 2:02 PM
Reposted by Erin Michos, MD
semeburka.bsky.social
For patients who can’t tolerate statins, or need more LDL-C lowering despite high-intensity therapy, bempedoic acid is a proven option that’s often overlooked.
@erinmichos.bsky.social @ciccaronecenter.bsky.social
Quick read our case 🔗 @accintouch.bsky.social

learn.acc.org/Page/Bempedo...
For patients who can’t tolerate statins, or need more LDL-C lowering despite high-intensity therapy, bempedoic acid is a proven option that’s often overlooked
July 16, 2025 at 2:43 PM
Reposted by Erin Michos, MD
ajpcardio.bsky.social
📢 New in AJPC: Study explores how gender and menopause status impact BP reduction in a mobile health self-management program for hypertension. @drmarthagulati.bsky.social @erinmichos.bsky.social

📱💡 Personalized care matters.

ow.ly/H8ob50WrnQk

#Hypertension #Cardiology #mHealth #AJPC
July 17, 2025 at 5:10 PM
Reposted by Erin Michos, MD
aspcardio.bsky.social
We’re proud to celebrate @ajpcardio.bsky.social — official journal of the ASPC — on its 2024 impact factor of 5.9 & ranking 34 of 230 journals in Cardiac & Cardiovascular Systems! Kudos Dr. Nathan Wong, @erinmichos.bsky.social, & the AJPC community for advancing the field of preventive cardiology.
ajpcardio.bsky.social American Journal of Preventive Cardiology @ajpcardio.bsky.social · Jun 19
AJPC has earned a new impact factor of 5.9 & is now ranked 34 out of 230 journals in Cardiac & Cardiovascular Systems!
Official journal @aspcardio.bsky.social, AJPC is on the rise — thanks to Dr. Nathan Wong, @erinmichos.bsky.social, & our incredible community.
www.sciencedirect.com/journal/amer...
June 19, 2025 at 4:08 PM
Reposted by Erin Michos, MD
patriciageorge5280.bsky.social
Having a great time and learning a ton at the @nationaljewish.org CV Symposium: Improving Cardiovascular Outcomes: The Next Era of Prevention. AND I got to see Dr. @erinmichos.bsky.social and ask her all my pressing cardiology questions. 🫀❤️👊
June 12, 2025 at 4:43 PM
Reposted by Erin Michos, MD
hancardiomd.bsky.social
The impact of federal actions on academic medicine and the U.S. health care system

www.aamc.org/about-us/aam...

@cardioobdoc.bsky.social @arghavansallesmd.medsky.social @erinmichos.bsky.social @drmarthagulati.bsky.social
June 12, 2025 at 1:00 AM
Reposted by Erin Michos, MD
fipco.bsky.social
Systemic review of discordance studies by Daniel Sehayek, et al. finds apoB generally outperforms LDL-C and non-HDL-C. (prior post of recent study adds to this evidence) #cardiosky

www.lipidjournal.com/article/S193...
June 11, 2025 at 1:19 AM
Reposted by Erin Michos, MD
ajpcardio.bsky.social
June 2025 #AJPC Editors’ Message @erinmichos.bsky.social & Dr. Nathan Wong! Dive into cutting-edge articles on AI, psychosocial stress, obesity, chylomicronemia, and more in #CVDPrevention. Plus, a preview of #ASPC2025!

www.sciencedirect.com/science/arti...
#CardioSky @aspcardio.bsky.social
June 10, 2025 at 12:27 AM
Reposted by Erin Michos, MD
hcplivenews.bsky.social
New at #HiD25: @erinmichos.bsky.social, director of women's cardiovascular health at Johns Hopkins University, met with us to discuss her presentation on postmenopausal hormone imbalance, obesity, and cardiovascular disease risk in women.

Watch the interview here: www.hcplive.com/view/post-me...
June 7, 2025 at 10:30 PM
Reposted by Erin Michos, MD
hopkinsheart.bsky.social
A huge congratulations to our Cardiology Fellowship APD, Dr. Anum Minhas, who was awarded the Young Author Achievement Award for @jaccjournals.bsky.social JACC Advances 💖
allisonghaysmd.bsky.social allisonghaysmd.bsky.social @allisonghaysmd.bsky.social · Apr 1
Congratulations to @anumminhas @theresaboyer
for wining JACC authorship awards for work in Maternal CV Health 👏🏼👏🏼👏🏼
@erinmichos.bsky.social
@hopkinsheart.bsky.social
@accintouch.bsky.social @janetcatov #acc2025
April 1, 2025 at 7:57 PM
Reposted by Erin Michos, MD
vindicomeded.bsky.social
🍳 FREE CME + breakfast + the latest breakthroughs in #ASCVD treatment

Fri, May 30 | 7:15–8:45 AM at JW Marriott Miami Turnberry Resort and Spa #NLASessions

🔗 vindicoce.com/NLA

@nationallipid.bsky.social @erinmichos.bsky.social @foundationofnla.bsky.social @lipidjournal.bsky.social
CE Breakfast Symposium during #NLASessions Lowering LDL-C: The Role of Emerging CETP Inhibitors in Reducing CV Risk Friday, May 30 at 7:15 AM
May 22, 2025 at 1:10 PM
Reposted by Erin Michos, MD
vindicomeded.bsky.social
Don’t miss the CETP comeback story—plus RAPID-FIRE ROUNDTABLE—at our CE breakfast on May 30 during #NLASessions Register here >> vindicoce.com/NLA
@erinmichos.bsky.social
@nationallipid.bsky.social
@lipidjournal.bsky.social
@foundationofnla.bsky.social
May 19, 2025 at 8:25 PM
erinmichos.bsky.social
Pleased to be a co-author of this study and part of TANDEM steering committee. Given the critical importance of reducing LDL Cholesterol for preventing atherosclerotic cardiovascular disease, more options to lower LDL-C is a good thing!
thelancet.com The Lancet @thelancet.com · May 16
Atherosclerotic cardiovascular disease (ASCVD) contributes substantially to the burden of cardiovascular disease.

A new trial suggests promise for broadening the therapeutic landscape for patients with pre-existing or high risk for ASCVD.

Find out more in our latest issue: tinyurl.com/4vjusubm
Cover of The Lancet May 17, 2025 issue. Quote on cover reads: "the demonstrated efficacy of the obicetrapib–ezetimibe FDC in the TANDEM trial holds promise for broadening the therapeutic landscape for patients with pre-existing or high risk for atherosclerotic cardiovascular disease."
May 18, 2025 at 5:44 PM
Reposted by Erin Michos, MD
cardioobdoc.bsky.social
Long-term trials of #colchicine for secondary prevention of vascular events: a meta-analysis

#CardioSky
academic.oup.com/eurheartj/ad...
@escardio.bsky.social @anastasiasmihaili.bsky.social @victoriadelgadomd.bsky.social @gimelliale.bsky.social @load-dependent.bsky.social @dmljmd.bsky.social
May 14, 2025 at 2:29 AM
erinmichos.bsky.social
Join me in Nashville Sept 5-7 for the American Society of Echocardiography @ase360.bsky.social Scientific Sessions and 50th year Anniversary! Join us for late breaking innovations & updates in cardiovascular ultrasound. #echofirst #ASE2025 #EchoSky
May 13, 2025 at 10:26 PM
Reposted by Erin Michos, MD
sharonnehayes.bsky.social
Just finished up a great 2 days of learning & developing solutions for better heart health for women at Hello Heart’s 2nd annual conference. Rock star faculty & engaged participants.
@erinmichos.bsky.social @jaynemorgan.bsky.social @womenheart.bsky.social
May 9, 2025 at 7:23 PM
erinmichos.bsky.social
Exciting news for #liver health! The #GLP1RA #semaglutide significantly improved #MASH & fibrosis.
nejm.org NEJM.org @nejm.org · Apr 30
In this interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results: nej.md/3EVFAFM

#MedSky #EndoSky #GastroSky
The figure shows the percentage of patients with fibrosis stage 2 or 3 who had resolution of steatohepatitis with no worsening of liver fibrosis (Panel A) and reduction in liver fibrosis with no worsening of steatohepatitis (Panel B) after 72 weeks, with the estimated difference expressed in percentage points.
May 8, 2025 at 2:30 AM